Quantcast

Latest Medicago Inc. Stories

2011-03-30 16:00:00

QUEBEC CITY, QC, March 30 /PRNewswire-FirstCall/ -  Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced its operational and financial results for the fourth quarter and year ended December 31, 2010. The Company's financial statements and management report are available at www.sedar.com and at www.medicago.com. Highlights...

2011-03-21 06:00:00

-The Company launches the clinical development of its seasonal flu vaccine- QUEBEC CITY, March 21 /PRNewswire-FirstCall/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that the first dose of vaccine has been administered thereby initiating the Company's phase I H1N1 influenza VLP vaccine candidate ("H1N1 vaccine")...

2011-03-15 06:00:00

APPROVED FOR PUBLIC RELEASE, DISTRIBUTION UNLIMITED RALEIGH AND QUEBEC CITY, March 15 /PRNewswire-FirstCall/ - Medicago USA Inc., a wholly owned subsidiary of Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has received the second milestone payment of US$3.8 million from the Defense Advanced Research Projects Agency...

2011-03-14 15:06:00

QUEBEC CITY, March 14 /PRNewswire/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that Mr. Pierre Labbe, Chief Financial Officer will present a corporate update at the 23(rd) Annual Roth OC Growth Stock Conference on Tuesday, March 15, 2011 at 8:00 a.m. Pacific Time at The Ritz Carlton Laguna Niguel in Dana Point,...

2011-02-15 06:00:00

QUEBEC CITY, Feb. 15 /PRNewswire-FirstCall/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that Ms. Nathalie Landry, Vice President of Product Development, is invited to present at the 7(th) WHO meeting on evaluation of pandemic influenza prototype vaccines in clinical trials. The conference is being held at the World...

2011-02-10 07:00:00

QUEBEC CITY, Feb. 10 /PRNewswire/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that Mr. Andy Sheldon, President and Chief Executive Officer of Medicago will be presenting at the 13th Annual BIO CEO & Investor Conference. The conference is being held at the Waldorf Astoria in New York City from February 14(th)-15(th),...

2011-02-08 07:44:00

-The Company launches the clinical development of its seasonal flu vaccine- QUEBEC CITY, Feb. 8 /PRNewswire-FirstCall/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has received Food and Drug Administration ("FDA") clearance for its phase I H1N1 influenza VLP vaccine candidate ("H1N1 vaccine") clinical trial in the...

2011-02-01 06:19:00

- Company's results continue to be amongst the best for influenza vaccine manufacturing technologies - -Company's VLP induced the production of antibodies that cross react with multiple strains of influenza- QUEBEC CITY, Feb. 1 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG) a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive interim results...

2011-01-11 07:00:00

-Proposed development of a single dose H5N1 influenza vaccine which could be rapidly and widely administered in the case of avian pandemic flu outbreak- -Approved for Public Release, Distribution Unlimited- QUEBEC CITY, Jan. 11 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it was selected to collaborate...

2011-01-05 07:00:00

QUEBEC CITY, Jan. 5 /PRNewswire-FirstCall/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that a scientific report entitled "Preclinical and Clinical Development of Plant-Made Virus-Like Particle Vaccine against Avian H5N1 Influenza," was recently published in the peer-reviewed journal PLoS ONE. Scientists from Medicago,...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.